2.54
+1.17(+85.40%)
Currency In USD
| Previous Close | 1.37 |
| Open | 1.72 |
| Day High | 2.75 |
| Day Low | 1.58 |
| 52-Week High | 16.64 |
| 52-Week Low | 1.17 |
| Volume | 78.72M |
| Average Volume | 3.43M |
| Market Cap | 15.38M |
| PE | -0.23 |
| EPS | -11.12 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 4.09 |
| Change | 1.17 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $14.39 as of August 05, 2025 at a share price of $2.54. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $3.54 as of August 05, 2025 at a share price of $2.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Aug 01, 2025 11:00 AM GMT
Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasd
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia Pre-Supplemental New Drug Application meeting with FDA scheduled for August 20, 2025
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Jul 01, 2025 11:00 AM GMT
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to d